The role of platelet function testing in risk stratification and clinical decision-making


Journal Article (Review)

Clopidogrel (a widely used second-generation thienopyridine) therapy is associated with an unpredictable pharmacodynamic response whereby approximately 1 in 3 patients will have a high on-treatment platelet reactivity to adenosine diphosphate. High on-treatment platelet reactivity is an established risk factor for ischemic event occurrence in patients undergoing percutaneous coronary intervention. Platelet function testing may have a role in monitoring therapeutic efficacy when clopidogrel is the chosen agent and in safety when more potent drugs are used, especially in patients with high bleeding risk. At this time, it seems most reasonable to assess platelet function in high-risk clopidogrel-treated patients. © 2013 Elsevier Inc.

Full Text

Duke Authors

Cited Authors

  • Gurbel, PA; Tantry, US

Published Date

  • October 1, 2013

Published In

Volume / Issue

  • 2 / 4

Start / End Page

  • 607 - 614

International Standard Serial Number (ISSN)

  • 2211-7458

Digital Object Identifier (DOI)

  • 10.1016/j.iccl.2013.05.009

Citation Source

  • Scopus